SCHEMBL5440288

SCHEMBL5440288

Cn1cc(-c2cc(Oc3ccc(F)c(NC(=O)c4ccc(Cl)c(C(F)(F)F)c4)c3)ncn2)cn1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.54
ABL1 P00519 2/20 0.47
CSF1R P07333 1/20 0.44
BRAF P15056 2/20 0.43
RAF1 P04049 1/20 0.42
MAPK3 P27361 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5417893 0.89 KDR (0.68) KDRBRAFRAF1MAPK3
SCHEMBL5432163 0.87 KDR (0.56) KDRABL1CSF1RBRAFRAF1
SCHEMBL5436585 0.82 KDR (0.70) KDRABL1BRAFRAF1MAPK3
SCHEMBL5423625 0.82 KDR (0.52) KDRBRAF
SCHEMBL5338781 0.82 ABL1 (0.41) KDRABL1CSF1R
SCHEMBL5460315 0.81 KDR (0.77) KDRBRAFRAF1MAPK3
SCHEMBL5450727 0.79 KDR (0.53) KDRBRAFRAF1
SCHEMBL5415362 0.79 BRAF (0.58) KDRBRAF
SCHEMBL5445003 0.79 KDR (0.69) KDRBRAFRAF1
SCHEMBL5448861 0.79 KDR (0.81) KDRABL1BRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155746-A1 NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155746-A1 NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155746-A1 NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155746-A1 NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 KDR 508/4885ABL1 57/4885CSF1R 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.